# US 2006/0156421 A1 · High throughput screening methods for anti-metastatic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0156421 A1
- Document ID: US20060156421A1
- Status: Published application
- Kind: A1
- Application number: 11/323,151
- Filed: 2005-12-30
- Published: 2006-07-13
- Earliest claimed: 2004-06-18
- Inventors: Ross Cagan
- Web page: https://patentgrep.com/patent/US20060156421A1

## CPC

- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 67/68: Genetically modified insects
- C07K 14/82: Translation products from oncogenes
- G01N 33/5085: {of invertebrates}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2217/058: due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
- A01K 2227/706: Insects, e.g. Drosophila melanogaster, medfly
- A01K 2267/0331: Animal model for proliferative diseases
- G01N 2333/43573: from Drosophila
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

High throughput methods for screening of anti-cancer compounds using Drosophila are described. The methods involve modifying the expression of dCsk and observing the effect of putative anti-cancer candidate compounds on resulting expressed characteristics in the Drosophila. Related animal models and apparatus are also provided.

## Claims

### Claim 1

A method for high throughput screening of compounds, the method comprising:
inducing a screenably distinct characteristic in wild-type Drosophila larvae by modifying expression of one or more Drosophila genes, said screenably distinct characteristic associated with human tumor metastasis;
exposing the Drosophila larvae to a compound that putatively modifies the screenably distinct characteristic; and
screening the Drosophila to determine whether the compound modifies the screenably distinct characteristic.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the screenably distinct characteristic comprises one of cell migration, apoptosis and abnormal tissue growth.

### Claim 3 (depends on 1)

A method according to claim 1, wherein inducing a screenably distinct characteristic in wild-type Drosophila using targeted expression of one or more Drosophila genes comprises modifying expression of one or more of Csk, Src, cadherin, P120-catenin Rho1, Jnk, metalloprotease MMP2, or DIAP1.

### Claim 4 (depends on 1)

A method according to claim 1, wherein modifying expression of one or more Drosophila genes comprises reducing or eliminating dCsk gene expression.

### Claim 5 (depends on 4)

A method according to claim 4, further comprising spatially limiting the reduction or elimination of dCsk gene expression.

### Claim 6 (depends on 5)

A method according to claim 5, comprising spatially limiting reduction or elimination of dCsk expression to the Drosophila developing eye.

### Claim 7 (depends on 5)

A method according to claim 5, comprising further spatially limiting reduction or elimination of dCsk expression to a plurality of discrete clonal patches having boundary cells adjacent to wild-type cells.

### Claim 8 (depends on 5)

A method according to claim 5, comprising spatially limiting reduction or elimination of dCsk expression to the Drosophila developing wing.

### Claim 9 (depends on 4)

A method according to claim 4, comprising reducing or eliminating dCsk gene expression in a developing Drosophila using an RNA interference construct.

### Claim 10 (depends on 1)

A method according to claim 1, further comprising screening the Drosophila to determine whether the compound has a toxic effect on the Drosophila.

### Claim 11

An animal model of human tumor metastasis comprising:
a Drosophila having spatially limited modified expression of dCsk.

### Claim 12 (depends on 11)

An animal model of human tumor metastasis according to claim 11, wherein dCsk expression is reduced in the Drosophila developing eye.

### Claim 13 (depends on 12)

An animal model of human tumor metastasis according to claim 12, wherein reduced dCsk expression is spatially limited to the Drosophila developing eye.

### Claim 14 (depends on 13)

An animal model of human tumor metastasis according to claim 13, wherein reduced dCsk expression is further spatially limited to a plurality of discrete clonal patches having boundary cells adjacent to wild-type cells.

### Claim 15 (depends on 11)

An animal model of human tumor metastasis according to claim 11, wherein dCsk expression is spatially limited to the Drosophila developing wing.

### Claim 16 (depends on 15)

An animal model of human tumor metastasis according to claim 15, wherein reduced dCsk expression is further spatially limited to a plurality of discrete clonal patches having boundary cells adjacent to wild-type cells.

### Claim 17

A bioassay method for assaying the effects of a candidate anti-metastatic compound, said method comprising:
modifying at least one of cell migration, apoptosis and abnormal tissue growth in a Drosophila by modifying expression of dCsk; and
exposing the Drosophila to a compound that putatively modifies at least one of cell migration, apoptosis and abnormal tissue growth.

### Claim 18 (depends on 17)

A bioassay method according to claim 17, wherein modifying expression of dCsk comprises spatially limiting the modified expression of dCsk.

### Claim 19 (depends on 18)

A bioassay method according to claim 18, wherein spatially limiting the modified expression of dCsk comprises reducing dCsk expression and spatially limiting reduced dCsk expression to the Drosophila developing eye.

### Claim 20 (depends on 18)

A bioassay method according to claim 18, wherein reduced dCsk expression is further spatially limited to a plurality of discrete clonal patches having boundary cells adjacent to wild-type cells.

### Claim 21 (depends on 18)

A bioassay method according to claim 18, wherein spatially limiting the modified expression of dCsk comprises reducing dCsk expression and spatially limiting reduced dCsk expression to the Drosophila developing wing.

### Claim 22 (depends on 21)

A bioassay method according to claim 21, wherein reduced dCsk expression is further spatially limited to a plurality of discrete clonal patches having boundary cells adjacent to wild-type cells.

### Claim 23

A bioassay method comprising:
in a first Drosophila, reducing dCsk expression and spatially limiting reduced dCsk expression to the Drosophila developing eye; and
in a second Drosophila, reducing dCsk expression in the Drosophila developing eye and further spatially limiting reduced dCsk to a plurality of discrete clonal patches having boundary cells adjacent to wild-type cells;
exposing the first Drosophila and the second Drosophila to a compound that putatively modifies at least one of cell migration, apoptosis and abnormal tissue growth; and
comparing the effect of the compound on at least one of cell migration, apoptosis and abnormal tissue growth in the first Drosophila and the second Drosophila.

### Claim 24

Apparatus for use in a high throughput screening assay method comprising:
a multi-well microtiter plate;
an amount of a Drosophila growth medium placed into said multiple wells of said multi-well microtiter plate;
an amount of a candidate compound added to said multiple wells; and
at least one Drosophila in each of said multiple wells, said Drosophila having modified dCsk expression and expression of at least one screenably distinct characteristic.

### Claim 25 (depends on 24)

Apparatus according to claim 24, wherein said Drosophila with modified expression of dCsk comprises a Drosophila with reduced or eliminated expression of dCsk gene.

### Claim 26 (depends on 24)

Apparatus according to claim 24, wherein said Drosophila having expression of at least one screenably distinct characteristic comprises a characteristic associated with human tumor metastasis.

### Claim 27 (depends on 26)

Apparatus according to claim 26, wherein the at least one screenably distinct characteristic is selected from the group consisting of cell migration, apoptosis and abnormal tissue growth.

### Claim 28 (depends on 26)

Apparatus according to claim 26, wherein the screenably distinct characteristic comprises abnormal tissue growth in the wing.

### Claim 29 (depends on 26)

Apparatus according to claim 26, wherein the screenably distinct characteristic comprises abnormal tissue growth in the eye.
